Cepheid
Miniaturized sample-to-answer devices in development hint at an evolving molecular diagnostics landscape but launch timelines for these platforms remain unclear.
The Danaher subsidiary's core revenues grew more than 90 percent in the first quarter of 2021 and it expects to ship 45 million SARS-CoV-2 tests for the year.
Danaher Q1 Revenues Up 58 Percent
The firm beat the consensus Wall Street estimate on the top line as its Life Sciences revenues grew 115 percent and its Diagnostics revenue rose 34 percent.
Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance
The company said it expects revenue growth to be approximately 57 percent year over year and non-GAAP core revenue growth to be approximately 29 percent.
FDA Posts Info on Impact of SARS-CoV-2 Mutations on Test Effectiveness
The FDA identified molecular tests from Mesa Biotech, Applied DNA Sciences, Thermo Fisher Scientific, and Cepheid that could be affected by certain mutations.